Subject of the day
KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
FY 2017–2025 · 7 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $389.13M | +33.9% | |
| Operating income | $65.75M | — | |
| Net income | $204.83M | — | |
| Cash from ops | -$88.80M | — |
$328.34
▼ -4.52 (-1.4%)
| 52w hi | $378.15 |
|---|---|
| 52w lo | $137.46 |
| Vol | 132.06K |
| As of | Aug 13 |
Our score +0.13
| Short | -0.10 |
|---|---|
| Medium | +0.24 |
| Long | +0.36 |
computed 2026-08-13
Krystal Biotech, Inc.
Healthcare · Biotechnology
| Market cap | $9.72B |
|---|---|
| Enterprise value | $9.02B |
| Trailing P/E | 41.09x |
| Forward P/E | 34.10x |
| EV / EBITDA | 45.24x |
| P / S (ttm) | 22.06x |
| Profit margin | 54.8% |
| Return on equity | 20.1% |
| Revenue growth | +24.1% |
| Earnings growth | +38.8% |
| Debt / equity | 0.65 |
| Beta vs SPX | 0.90 |
|---|---|
| Corr SPX | 0.35 |
| Annual vol | 42.2% |
| Annual ret | +39.2% |
| Sharpe | 0.93 |
| Max DD | -39.5% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.27 | |
| Sector | +0.12 | |
| Technical | +0.00 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $334.00 | $334.88 | $327.34 | $328.34 | 132.06K |
| Aug 12 | $326.95 | $334.21 | $325.00 | $332.86 | 161.90K |
| Aug 11 | $333.30 | $336.28 | $324.34 | — | 140.76K |
| Aug 10 | $324.54 | $332.73 | $324.54 | $331.59 | 151.90K |
| Aug 7 | $326.34 | $329.00 | $320.34 | $326.45 | 160.00K |